AdaptHealth Corp. announced on July 20, 2026, the sale of its Diabetes Health business to Cardinal Health, Inc. for $235 million in cash. The all-cash transaction allows AdaptHealth to pay down debt and sharpen its focus on its core respiratory and home medical equipment operations. The deal is expected to close in the second half of 2026, pending customary regulatory approvals. This move follows AdaptHealth's strategic review initiated earlier in the year to optimize its portfolio structure.
Context — why this matters now
The transaction occurs amidst sustained pressure on healthcare distributors and post-acute care providers. The sector faces margin compression from inflation in supply chain costs and intensifying reimbursement pressures from both government and private payers. Macro conditions remain a headwind, with the 10-year Treasury yield at 4.2%, elevating the cost of capital and making debt reduction a priority for leveraged companies. For AdaptHealth, this sale represents a decisive step in a multi-year pivot away from its 2021 merger with Apria, which combined disparate home medical equipment businesses.
The sale is comparable to prior healthcare portfolio rationalizations, such as Medline Industries' 2023 sale of its medical kitting business to private equity for an undisclosed sum. More directly, it mirrors Owens & Minor's 2024 divestiture of its European surgical supply division for approximately $180 million. Both moves were executed to streamline operations and bolster balance sheets during periods of sector-wide margin stress. The catalyst for AdaptHealth's immediate action was likely heightened scrutiny from creditors and investors following its latest quarterly earnings, which highlighted the diabetes segment's lower growth profile.
Data — what the numbers show
The Diabetes Health unit generated approximately $435 million in revenue over the last twelve months, representing about 16% of AdaptHealth's total consolidated revenue of $2.72 billion. The $235 million sale price implies a revenue multiple of roughly 0.54x, a discount to the broader healthcare distribution sector's average. This compares to a sector median enterprise value-to-revenue multiple of 0.7x for comparable medical supply distributors. The transaction will reduce AdaptHealth's net leverage ratio by an estimated 0.4x, moving it closer to its stated target of 3.0x to 3.5x.
The sale involves transferring an unspecified number of employees and a nationwide network of distribution and clinical support infrastructure to Cardinal Health. AdaptHealth's stock (AHCO) closed the prior session at $7.85, down 44% year-to-date, while Cardinal Health's stock (CAH) was at $95.60, up 12% YTD. The deal value is approximately 8.5% of AdaptHealth's current market capitalization of $2.76 billion. Cardinal Health's medical segment, which will absorb the unit, reported $20.1 billion in fiscal 2025 revenue.
| Metric | AdaptHealth Diabetes Unit | Cardinal Health Medical Segment |
|---|
| Trailing Revenue | ~$435M | ~$20.1B |
| Implied EV/Revenue Multiple | ~0.54x | NA |
| YTD Stock Performance | -44% (Parent Co.) | +12% |
Analysis — what it means for markets / sectors / tickers
The immediate beneficiary is Cardinal Health (CAH), which expands its diabetes consumables footprint and gains a direct-to-patient service channel. The acquisition is accretive to Cardinal's medical segment margins, as it integrates a lower-margin business into a larger, more efficient platform. Suppliers of continuous glucose monitors and insulin pumps, like DexCom (DXCM) and Insulet (PODD), may see a more consolidated and powerful distributor partner in Cardinal Health, potentially improving logistics but increasing customer concentration risk. The deal is a net negative for smaller, pure-play diabetes supply companies like Nutex Health, which now face a larger, integrated competitor.
For AdaptHealth (AHCO), the transaction removes a slower-growing, capital-intensive division, allowing management to focus capital on higher-margin respiratory and home infusion therapies. The primary risk is execution; the company must successfully redeploy the cash proceeds to reduce interest expense without stifling growth in its remaining segments. A counter-argument suggests selling a revenue-generating asset during a downturn may leave the company smaller and more reliant on a single business line. Positioning data shows short interest in AHCO has climbed to 18% of float in recent weeks, while CAH has seen steady institutional accumulation.
Outlook — what to watch next
The primary catalyst is the deal's closing, expected in Q3 or Q4 of 2026. Failure to secure regulatory approval by year-end would be a significant negative surprise for AHCO shareholders. Investors will scrutinize AdaptHealth's Q3 2026 earnings report for updated full-year guidance excluding the diabetes unit and details on the use of proceeds for debt repayment. For Cardinal Health, the focus will be on its fiscal Q1 2027 earnings for initial commentary on integration costs and synergies.
Key levels to watch include AHCO's stock reaction to the $7.50 support level, a breach of which could signal continued skepticism. The company's net leverage ratio, aiming for 3.0x, will be a critical metric in subsequent quarters. For the broader medical supplies sector, the deal's valuation multiple will serve as a benchmark for future divestitures, potentially pressuring peers with complex portfolios to consider similar streamlining moves.
Frequently Asked Questions
How does this sale affect AdaptHealth's debt situation?
The $235 million cash proceeds are earmarked primarily for debt reduction. AdaptHealth's consolidated net debt was approximately $1.8 billion prior to the announcement. Paying down this amount will lower annual interest expense and improve the company's leverage ratios, a key concern for credit rating agencies. This deleveraging is intended to provide greater financial flexibility to manage reimbursement challenges and invest in its core respiratory business.
What does Cardinal Health gain from buying this business?
Cardinal Health acquires a direct national platform for diabetes supplies, complementing its existing pharmaceutical distribution strength. The unit provides a recurring revenue stream from a chronic condition population. It enhances Cardinal's presence in the home-based care continuum, a strategic growth area. The integration allows Cardinal to apply its scale and distribution efficiency to improve the unit's operating margins over time.
What is the historical context for healthcare distributors selling business units?
Portfolio rationalization is common during periods of sector margin pressure. Baxter International sold its biopharma solutions unit in 2023 for $4.25 billion to focus on core hospital products. Owens & Minor divested its European business in 2024. These moves reflect a strategic shift towards simplification, core competency focus, and balance sheet repair when broad-based growth becomes challenging, mirroring AdaptHealth's current rationale.
Bottom Line
AdaptHealth is selling a slower-growth division to fortify its balance sheet and concentrate on its primary respiratory care business.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
